A lens on the final formulation and fill & finish process: considerations for process automation and device development

The last place where you want your cell therapy manufacturing process to go wrong is the final key step: final formulation & fill/finish! In this webinar, we review this critical step of the process under the lens of moving from a manual system to automation for commercial production. What are the key considerations and parameters to review, the issues and complications that you need to address, and associated trade-offs when selecting a device/process. Finally, we explore the thought process in assessing in the development of a device to allow the migration from a manual process to an automated solution.

• An overview of the final formulation and fill & finish processing step for cell & gene therapies and associated key considerations
• The pros and cons of manual and automated processing in this critical step and how these change over the development lifecycle of the product
• Obtain a perspective with the lens from both early stage and commercial manufacturing and how that factors into the development of an automated solution
• The trade-offs in the development of a process and the technology to execute that process

[#speakersPlaceHolder]

Kyle Massey

Systems Engineer at Terumo BCT

Kyle currently serves as technical and project lead for development of Cell Therapy Technologies at Terumo BCT. Throughout his seven-year career, he has worked on various engineering and software development teams at Terumo BCT to develop cellular therapy and automated blood collection devices.

Michael Covington

Vice President, Regulatory CMC at Orchard Therapeutics

Michael is an expert in the human therapeutic biotechnology and biologics fields in areas including Regulatory Affairs, Quality, Compliance, and Manufacturing.  He has provided leadership for companies developing recombinant proteins, monoclonal antibodies, cellular, and genetic therapies primarily for the treatment of Cancer and Rare Diseases including Amgen, Dendreon, and Juno Therapeutics.  Michael is currently the Vice President of Regulatory CMC for Orchard Therapeutics.

Dalip Sethi

Manager, Senior Scientist at Terumo BCT

Dalip currently serves as the scientific development lead for the Cell Therapy Technologies portfolio at Terumo BCT. He holds a doctorate degree and conducted post-doctoral studies at Thomas Jefferson University, School of Medicine. Prior to Terumo BCT, Dalip was engaged in the development of technologies & methods for use in autologous cell therapy applications. Throughout his career, Dalip has authored multiple scientific publications and is a co-inventor on several patents & patent applications.

Watch now

SPEAKERS

Kyle Massey

Systems Engineer at Terumo BCT

Michael Covington

Vice President, Regulatory CMC at Orchard Therapeutics

Dalip Sethi

Manager, Senior Scientist at Terumo BCT

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 69

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 40

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 34

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 33

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 32

Days

Register